JP6847851B2 - Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 - Google Patents

Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 Download PDF

Info

Publication number
JP6847851B2
JP6847851B2 JP2017553877A JP2017553877A JP6847851B2 JP 6847851 B2 JP6847851 B2 JP 6847851B2 JP 2017553877 A JP2017553877 A JP 2017553877A JP 2017553877 A JP2017553877 A JP 2017553877A JP 6847851 B2 JP6847851 B2 JP 6847851B2
Authority
JP
Japan
Prior art keywords
methyl
pyrido
oxo
trifluoromethyl
pyrazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017553877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511627A (ja
JP2018511627A5 (https=
Inventor
ヴォルグラフ，マシュー
ジャン，ユ
ヴィルミュール，エリシア
セラーズ，ベンジャミン
ウー，グオシェン
ルウ，アイジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2018511627A publication Critical patent/JP2018511627A/ja
Publication of JP2018511627A5 publication Critical patent/JP2018511627A5/ja
Application granted granted Critical
Publication of JP6847851B2 publication Critical patent/JP6847851B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017553877A 2015-04-15 2016-04-12 Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用 Active JP6847851B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015076617 2015-04-15
CNPCT/CN2015/076617 2015-04-15
PCT/EP2016/057962 WO2016166078A1 (en) 2015-04-15 2016-04-12 Pyridopyrimidinones and their use as nmda receptor modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020200946A Division JP2021046428A (ja) 2015-04-15 2020-12-03 Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Publications (3)

Publication Number Publication Date
JP2018511627A JP2018511627A (ja) 2018-04-26
JP2018511627A5 JP2018511627A5 (https=) 2019-05-16
JP6847851B2 true JP6847851B2 (ja) 2021-03-24

Family

ID=55809078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017553877A Active JP6847851B2 (ja) 2015-04-15 2016-04-12 Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
JP2020200946A Pending JP2021046428A (ja) 2015-04-15 2020-12-03 Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020200946A Pending JP2021046428A (ja) 2015-04-15 2020-12-03 Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用

Country Status (19)

Country Link
US (1) US10280165B2 (https=)
EP (1) EP3283487B1 (https=)
JP (2) JP6847851B2 (https=)
KR (1) KR20170137137A (https=)
CN (1) CN107531696B (https=)
AU (1) AU2016248886B2 (https=)
BR (1) BR112017021083A2 (https=)
CA (1) CA2982217A1 (https=)
CL (1) CL2017002498A1 (https=)
CO (1) CO2017009989A2 (https=)
CR (1) CR20170462A (https=)
IL (1) IL254921B (https=)
MX (1) MX373162B (https=)
PE (1) PE20180316A1 (https=)
PH (1) PH12017501876A1 (https=)
RU (1) RU2717665C2 (https=)
SG (1) SG11201708294YA (https=)
UA (1) UA120647C2 (https=)
WO (1) WO2016166078A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3055315T (lt) 2013-10-11 2018-10-25 F. Hoffmann-La Roche Ag Tiazolpirimidinonai kaip nmda receptorių aktyvumo moduliatoriai
RU2717665C2 (ru) 2015-04-15 2020-03-24 Ф. Хоффманн-Ля Рош Аг Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス，インコーポレーテッド ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
AR115905A1 (es) 2018-08-03 2021-03-10 Cadent Therapeutics Inc 5-(3-cloro-4-fluorofenil)-7-ciclopropil-3-(2-(3-fluoro-3-metilazetidin-1-il)-2-oxoetil)-3,7-dihidro-4h-pirrolo[2,3-d]pirimidin-4-ona como modulador de los receptores de nmda
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
JP7741100B2 (ja) 2020-05-04 2025-09-17 アムジェン インコーポレイテッド ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
CN1809563A (zh) * 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
AU2008213836A1 (en) * 2007-02-05 2008-08-14 Xenon Pharmaceuticals Inc. Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions
KR101811549B1 (ko) * 2013-06-19 2017-12-26 에프. 호프만-라 로슈 아게 인돌린-2-온 또는 피롤로-피리딘/피리미딘-2-온 유도체
LT3055315T (lt) * 2013-10-11 2018-10-25 F. Hoffmann-La Roche Ag Tiazolpirimidinonai kaip nmda receptorių aktyvumo moduliatoriai
RU2717665C2 (ru) 2015-04-15 2020-03-24 Ф. Хоффманн-Ля Рош Аг Пиридопиримидиноны и их применение в качестве модуляторов рецептора n-метил-d-аспартата

Also Published As

Publication number Publication date
CL2017002498A1 (es) 2018-04-20
PE20180316A1 (es) 2018-02-09
WO2016166078A1 (en) 2016-10-20
BR112017021083A2 (pt) 2018-07-03
JP2021046428A (ja) 2021-03-25
CA2982217A1 (en) 2016-10-20
MX2017013101A (es) 2018-01-30
CN107531696A (zh) 2018-01-02
RU2717665C2 (ru) 2020-03-24
AU2016248886A1 (en) 2017-10-12
RU2017139254A (ru) 2019-05-15
PH12017501876A1 (en) 2018-02-26
HK1245259A1 (zh) 2018-08-24
MX373162B (es) 2020-04-21
SG11201708294YA (en) 2017-11-29
CN107531696B (zh) 2021-03-16
US10280165B2 (en) 2019-05-07
IL254921B (en) 2021-02-28
KR20170137137A (ko) 2017-12-12
EP3283487A1 (en) 2018-02-21
JP2018511627A (ja) 2018-04-26
AU2016248886B2 (en) 2020-09-10
IL254921A0 (en) 2017-12-31
UA120647C2 (uk) 2020-01-10
CO2017009989A2 (es) 2018-01-05
EP3283487B1 (en) 2019-10-16
US20180127414A1 (en) 2018-05-10
RU2017139254A3 (https=) 2019-09-30
CR20170462A (es) 2018-02-01

Similar Documents

Publication Publication Date Title
JP6847851B2 (ja) Ｎｍｄａ受容体のモジュレーターとしてのピリドピリミジノン及びその使用
AU2017245125B2 (en) Heterocyclic compound
US10590079B2 (en) Cyano-substituted indoles as LSD1 inhibitors
CN103848785B (zh) 一类氘代3-氰基喹啉类化合物、其药用组合物、制备方法及其用途
US10604502B2 (en) Substituted 5-cyanoindole compounds and uses thereof
JP6419800B2 (ja) Ｎｍｄａ受容体活性の調節因子としてのチアゾロピリミジノン
JP6787913B2 (ja) 複素環化合物
TW200911254A (en) Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842
JP7088906B2 (ja) Ｆｇｆｒ４阻害剤並びにその製造方法及び使用
KR20230129627A (ko) 페닐-2-히드록시-아세틸아미노-2-메틸-페닐 화합물
US20220135579A1 (en) 2'-isopropyl-spiro (3,3'-pyrrolidine oxindole) liver x receptor regulator, preparation method therefor, and use thereof
JP2022549866A (ja) Ｃｒａｃ阻害剤としての２ｈ－ベンゾピラン誘導体
WO2022206724A1 (zh) 杂环类衍生物及其制备方法和用途
TW201331202A (zh) ［１，２，４］三唑并吡啶及其作為磷酸二酯酶抑制劑之用途
JP2015006994A (ja) ジヒドロイミダゾオキサゾール誘導体
HK1245259B (zh) 作为nmda受体调节剂的吡啶并嘧啶酮类及它们的用途
RU2791533C2 (ru) Гетероциклическое соединение
KR20260008767A (ko) 신규한 카복사마이드 유도체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171220

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201203

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20201215

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210119

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210303

R150 Certificate of patent or registration of utility model

Ref document number: 6847851

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250